IOLCP Q4 FY26 Revenue Surges 17.4% to ₹619.5 Cr, PAT Jumps 68.2%
IOL Chemicals and Pharmaceuticals Limited reported its Q4 FY26 results, achieving a record quarterly revenue of ₹619.5 crore, up 17.4% YoY. PAT surged 68.2% to ₹53.2 crore. For FY26, revenue was ₹2319.1 crore, with PAT at ₹137.7 crore. The company incurred ₹164 crore capex for expansion.
The announcement details record-breaking financial performance, substantial year-on-year growth across key financial metrics, and strategic investments in capacity expansion, which are all significant factors for investors.
The company reported record quarterly revenue, significant year-on-year growth in revenue, EBITDA, and PAT, alongside positive commentary from the Joint Managing Director about strong performance and future growth drivers.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its financial results for the quarter and full year ended March 31, 2026. The company achieved its highest-ever quarterly revenue, reaching ₹619.5 crore, a 17.4% year-on-year increase. EBITDA for the quarter grew by 39.8% to ₹94.3 crore, and Profit After Tax (PAT) surged by 68.2% to ₹53.2 crore.
For the full fiscal year 2026, revenue stood at ₹2319.1 crore, up 11.5% from the previous year. EBITDA for FY26 increased by 29.3% to ₹290.4 crore, and PAT rose by 36.4% to ₹137.7 crore.
The Pharmaceuticals business saw strong growth, driven by increasing contributions from its non-Ibuprofen portfolio, including key products like Paracetamol and Metformin. The Chemicals business also performed well, with segment EBIT nearly doubling year-on-year, supported by improved realisations and stable demand. The company incurred capital expenditure of approximately ₹164 crore during the year for capacity expansion, product and infrastructure development, process automation, and operational improvements, funded through internal accruals.
Mr. Vikas Gupta, Joint Managing Director, stated that the strong performance was driven by healthy momentum across both businesses, with significant improvements in profitability and margin expansion due to a better product mix and focus on operational efficiencies. He added that capacity additions in select non-ibuprofen APIs and in chemicals like Ethyl Acetate, Acetic Anhydride, and Triacetin will further strengthen manufacturing capabilities and drive future growth.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.